DarioHealth Corp. Form 8-K Summary
Business Context and Reporting Period
Company: DarioHealth Corp. (DRIO)
Filing Date: May 20, 2025
Reporting Period: Current Report (Event Date: May 20, 2025)
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Capital Market. This filing addresses amendments to the terms of its preferred stock classes.
Key Financial Metrics
This Form 8-K is a current report regarding corporate governance and capital structure amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The Company amended the Certificates of Designation for its Series C, Series C-1, and Series C-2 Preferred Stock. The material changes include:
- Conversion Period Extension: The mandatory conversion period was extended from 15 months to 24 months from the original issue date.
- Dividend Provision: The Company will issue a dividend equal to 15% of the number of Common Stock shares issuable upon conversion for each full quarter anniversary of holding following the filing date.
- Capital Impact: No additional securities were issued or sold as a result of this filing.
Guidance, Outlook, and Risks
Management Commentary: The amendments were executed upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock. The filing was intended solely to amend and restate the terms mentioned above.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the structural changes to the preferred stock terms. The full text of the amended certificates is referenced in Exhibits 3.1, 3.2, and 3.3.
Investor Verification Checklist
- Verify the specific terms of the 15% dividend calculation in the attached Exhibits 3.1, 3.2, and 3.3.
- Confirm the exact original issue dates for Series C, C-1, and C-2 stock to calculate the new 24-month mandatory conversion deadlines.
- Review the impact of the extended conversion period on the Company's future capital structure and potential dilution.
- Check for any subsequent filings regarding the actual issuance of the quarterly dividends.